Observational Study
Copyright ©The Author(s) 2017.
World J Virol. Nov 12, 2017; 6(4): 59-72
Published online Nov 12, 2017. doi: 10.5501/wjv.v6.i4.59
Table 6 Univariable and multivariable logistic regression analysis of factors associated with SVR12 for 215 patients treated with sofosbuvir/ribavirin and a confirmed outcome
OR95%CIP valueOR95%CIP value
Age, per yr0.980.95-1.010.14
Race, black0.330.13-0.800.02
Gender, female1.961.08-3.650.03
BMI, per kg/m20.960.90-1.010.15
Naïve to treatment1.240.71-2.190.45
PI failure0.330.11-0.890.03
HCV viral load, per log IU/mL0.800.56-1.110.2
HCV genotype
27.240.57-1.29< 0.014.662.06-11.42< 0.01
33.291.55-7.37< 0.012.761.22-6.590.02
Hemoglobin, per g/dL1.110.95-1.320.17
Platelet, per 103/μL1.011.01-1.02< 0.01
ALT, per U/L10.99-1.000.1
AST, per U/L0.990.99-1.00< 0.01
Total bilirubin, per mg/dL0.370.24-0.55< 0.010.470.30-0.69< 0.01
Albumin, per g/dL3.151.98-5.19< 0.01
FIB-4 ≥< 0.01

  • Citation: Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World J Virol 2017; 6(4): 59-72
  • URL: https://www.wjgnet.com/2220-3249/full/v6/i4/59.htm
  • DOI: https://dx.doi.org/10.5501/wjv.v6.i4.59